1-10 of 10
Alessandra Tosolini
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase 2 Multicenter Trial of Tagraxofusp in Combination with Venetoclax and Azacitidine in Adults with Previously Untreated CD123+ Acute Myeloid Leukemia Ineligible for Intensive Chemotherapy

Naval Daver, Naveen Pemmaraju, Mikkael A. Sekeres, Amir T. Fathi, Andrew A. Lane, Anna Compagnoni, Ira Gupta, Alessandra Tosolini, Jessica Garzon, Hagop M. Kantarjian
Journal: Blood
Blood (2024) 144 (Supplement 1): 4265.1.
https://doi.org/10.1182/blood-2024-193593
Published: 2024
Journal Articles

Can Patient-Reported Ocular Symptoms Guide Dose Modifications in Patients with Relapsed/Refractory Multiple Myeloma Receiving Belantamab Mafodotin?

Rakesh Popat, Ashraf Z. Badros, Shaji Kumar, Paula Rodríguez-Otero, Adam D. Cohen, Salomon Manier, Peter M. Voorhees, Francesca Gay, Robert M. Rifkin, Thomas Martin, Ajai Chari, Katja Weisel, Asim V. Farooq, Bennie H. Jeng, Wee Joo Chng, Hans C. Lee, Jesus Berdeja, Vinay Jadhav, Alessandra Tosolini, Laurie Eliason, Antonio Palumbo, Meletios A. Dimopoulos, Sagar Lonial, Suzanne Trudel, Paul G. Richardson, Evangelos Terpos
Journal: Blood
Blood (2021) 138 (Supplement 1): 2746.
https://doi.org/10.1182/blood-2021-152681
Published: 2021
Journal Articles

Molecular remission and response patterns in patients with mutant- IDH2 acute myeloid leukemia treated with enasidenib

Clinical Trials & Observations
Eytan M. Stein, Courtney D. DiNardo, Amir T. Fathi, Daniel A. Pollyea, Richard M. Stone, Jessica K. Altman, Gail J. Roboz, Manish R. Patel, Robert Collins, Ian W. Flinn, Mikkael A. Sekeres, Anthony S. Stein, Hagop M. Kantarjian, Ross L. Levine, Paresh Vyas, Kyle J. MacBeth, Alessandra Tosolini, Jason VanOostendorp, Qiang Xu, Ira Gupta, Thomas Lila, Alberto Risueno, Katharine E. Yen, Bin Wu, Eyal C. Attar, Martin S. Tallman, Stéphane de Botton
Journal: Blood
Blood (2019) 133 (7): 676–687.
https://doi.org/10.1182/blood-2018-08-869008
Published: 2019
Includes: Supplemental data
Journal Articles

Comprehensive Genomic Analysis of IDH Inhibitor-Treated AML Samples Delineates Molecular Mechanisms of Differentiation and Heterogeneous Patterns of Acquired Resistance

Feng Wang, PhD, Kiyomi Morita, MD, Courtney D. DiNardo, MDMSc, Keyur Patel, MD PhD, Kyle MacBeth, PhD, Alessandra Tosolini, BS, Mark G. Frattini, MD, Jairo Matthews, BA, Latasha Little, Curtis Gumbs, Samantha Tippen, Xingzhi Song, PhD, Jianhua Zhang, PhD, Erika Thompson, MS, Tapan M. Kadia, MD, Guillermo Garcia-Manero, MD, Elias J. Jabbour, MD, Farhad Ravandi, MD, Marina Y. Konopleva, MD PhD, Hagop M. Kantarjian, MD, Andrew Futreal, PhD, Koichi Takahashi, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 441.
https://doi.org/10.1182/blood-2018-99-116383
Published: 2018
Journal Articles

Enasidenib Monotherapy Is Effective and Well-Tolerated in Patients with Previously Untreated Mutant- IDH2 (m IDH2 ) Acute Myeloid Leukemia (AML)

Daniel A. Pollyea, MD, Martin S. Tallman, MD, Stephane De Botton, Courtney D. DiNardo, MDMSc, Hagop M. Kantarjian, MD, Robert H. Collins, MD, Anthony S. Stein, MD, Qiang Xu, PhD, Alessandra Tosolini, BS, Ira Gupta, MD, Samuel V. Agresta, MD, Eytan M. Stein, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 638.
https://doi.org/10.1182/blood.V130.Suppl_1.638.638
Published: 2017
Journal Articles

Continuing Enasidenib Treatment for Patients with Mutant- IDH2 (m IDH2 ) Relapsed or Refractory Acute Myeloid Leukemia (R/R AML) with Stable Disease May Result in Improved Survival and Responses over Time

Eytan M. Stein, MD, Richard M. Stone, MD, Daniel A. Pollyea, MD, Gail J. Roboz, MD, Jessica K. Altman, MD, Courtney D. DiNardo, MDMSc, Stephane de Botton, MD PhD, Nora Tu, PhD, Arlene S. Swern, PhD, Alessandra Tosolini, BS, Ira Gupta, MD, Samuel V. Agresta, MD, Amir T. Fathi, MD MD BS
Journal: Blood
Blood (2017) 130 (Supplement 1): 1299.
https://doi.org/10.1182/blood.V130.Suppl_1.1299.1299
Published: 2017
Journal Articles

Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia

Clinical Trials & Observations
Eytan M. Stein, Courtney D. DiNardo, Daniel A. Pollyea, Amir T. Fathi, Gail J. Roboz, Jessica K. Altman, Richard M. Stone, Daniel J. DeAngelo, Ross L. Levine, Ian W. Flinn, Hagop M. Kantarjian, Robert Collins, Manish R. Patel, Arthur E. Frankel, Anthony Stein, Mikkael A. Sekeres, Ronan T. Swords, Bruno C. Medeiros, Christophe Willekens, Paresh Vyas, Alessandra Tosolini, Qiang Xu, Robert D. Knight, Katharine E. Yen, Sam Agresta, Stephane de Botton, Martin S. Tallman
Journal: Blood
Blood (2017) 130 (6): 722–731.
https://doi.org/10.1182/blood-2017-04-779405
Published: 2017
Includes: Supplemental data
Journal Articles

Enasidenib (AG-221), a Potent Oral Inhibitor of Mutant Isocitrate Dehydrogenase 2 ( IDH2 ) Enzyme, Induces Hematologic Responses in Patients with Myelodysplastic Syndromes (MDS)

Eytan M. Stein, MD, Amir T. Fathi, MD, Courtney D DiNardo, MD, Daniel A Pollyea, MD, Ronan T Swords, MD PhD FRCPI, FRCPath, Gail J. Roboz, MD, Robert Collins, Mikkael A. Sekeres, MD, Richard M. Stone, MD, Eyal C Attar, Alessandra Tosolini, BS, Qiang Xu, PhD, Michael Amatangelo, PhD, Ira Gupta, MD, Robert D. Knight, MD, Stéphane De Botton, MD PhD, Martin S. Tallman, MD, Hagop M. Kantarjian, MD
Journal: Blood
Blood (2016) 128 (22): 343.
https://doi.org/10.1182/blood.V128.22.343.343
Published: 2016
Journal Articles

Evaluation of the Pharmacokinetics of AG-221, a Potent Mutant IDH2 Inhibitor, in Patients with IDH2-Mutation Positive Advanced Hematologic Malignancies in a Phase 1/2 Trial

Yue Gao, PhD, Bin Fan, PhD, Kha Le, PhD, Erika Manyak, BASc, Hua Yang, PhD, Katherine Yen, PhD, Sam Agresta, MD, Eyal C. Attar, MD, Jian Chen, PhD, Qiang Xu, PhD, Alessandra Tosolini, BS, Jay M. Mei, MD PhD, Anjan Thakurta, Robert D. Knight, MD, Yan Li, PhD
Journal: Blood
Blood (2015) 126 (23): 2509.
https://doi.org/10.1182/blood.V126.23.2509.2509
Published: 2015
Journal Articles

Safety and Efficacy of AG-221, a Potent Inhibitor of Mutant IDH2 That Promotes Differentiation of Myeloid Cells in Patients with Advanced Hematologic Malignancies: Results of a Phase 1/2 Trial

Eytan M. Stein, MD, Courtney DiNardo, MD, Jessica K. Altman, MD, Robert Collins, MD, Daniel J. DeAngelo, MD PhD, Hagop M. Kantarjian, MD, Mikkael A. Sekeres, MD MS, Amir T. Fathi, MD, Ian W. Flinn, MD PhD, Arthur E. Frankel, MD, Ross L. Levine, MD, Bruno C. Medeiros, MD, Manish R. Patel, MD, Daniel Pollyea, MD MS, Gail J. Roboz, MD, Richard M. Stone, MD, Ronan T. Swords, MDPhDFRCPI FRCPath, Martin S. Tallman, MD, Katherine Yen, PhD, Eyal C. Attar, MD, Qiang Xu, PhD, Alessandra Tosolini, BS, Jay M. Mei, MD PhD, Anjan Thakurta, Robert D. Knight, MD, Stéphane De Botton, MD PhD
Journal: Blood
Blood (2015) 126 (23): 323.
https://doi.org/10.1182/blood.V126.23.323.323
Published: 2015